Replimune Gets Third Try at FDA Approval After Makary Departure
RSS SUMMARY · AGGREGATED FROM TWSJ
Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
World News
Opinion | India Is Losing Its Economic Edge
TWSJ·52m ago·3 min read
Business
Months after the Supreme Court struck down President Trump’s most sweeping global tariffs, the administration said it would levy new tariffs using a different legal mechanism
TWSJ·1h ago·3 min read
Business
Terms Revealed for SpaceX’s Unconventional $75 Billion IPO
TWSJ·1h ago·3 min read
Business
Sticker Shock at the Pump Fuels a Surge in Hybrid Sales
TWSJ·1h ago·3 min read
Related
On this beat
Business
After the Collapse of Spirit Airlines, This Major Budget Carrier Just Became the Target of a $4.1 Billion Takeover
INC·1h ago·3 min read
Business
How a Biotech Startup Is Using Dogs and AI to Rewrite the Rules of Cancer Screening
INC·1h ago·3 min read
Business
Elon Musk, Tesla face serious new threat
THE STREET·56m ago·3 min read
Business
Another airline files for bankruptcy and cancels flights
THE STREET·33m ago·3 min read